Skip to main content

Advertisement

Table 1 Summary of Demographic Characteristics

From: Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy

  6- and 7-Year Olds 8- to 12-Year Olds
  ATX PBO   ATX PBO  
Subject Characteristics N = 184 N = 96 pa N = 544 N = 316 pa
Gender, n (%)       
   Female 54 (29.3) 22 (22.9) .262 137 (25.2) 78 (24.7) .935
   Male 130 (70.7) 74 (77.1)   407 (74.8) 238 (75.3)  
Age (years), mean (SD) 7.2 (0.6) 7.1 (0.5) . 273b 10.2 (1.4) 10.2 (1.4) .606b
Origin, n (%)       
   African descent 16 (8.7) 15 (15.6) .179 81 (14.9) 40 (12.7) .442
   Caucasian 137 (74.5) 64 (66.7)   374 (68.8) 234 (74.1)  
   Hispanic 22 (12.0) 9 (9.4)   59 (10.8) 27 (8.5)  
   Other 9 (4.9) 8 (8.3)   30 (5.5) 15 (4.7)  
Prior stimulant treatment, n (%)       
   No 133 (72.3) 68 (70.8) .889 235 (43.3) 141 (44.6) .722
   Yes 51 (27.7) 28 (29.2)   308 (56.7) 175 (55.4)  
ADHD Subtype, n (%)       
   Hyperactive/impulsive 10 (5.4) 2 (2.1) .395 10 (1.8) 5 (1.6) .828
   Inattentive 26 (14.1) 12 (12.5)   148 (27.2) 92 (29.1)  
   Combined 148 (80.4) 82 (85.4)   386 (71.0) 219 (69.3)  
ADHD Severity, mean (SD)       
   Baseline ADHD Total T score 83.4 (9.5) 83.2 (8.7) .862 81.7 (11.6) 81.2 (11.2) .512
   Baseline CGI-ADHD-S score 5.0 (0.8) 5.0 (0.7) .743 4.9 (0.8) 4.9 (0.8) .909
  1. Abbreviations: ADHD = attention-deficit/hyperactivity disorder; ATX = atomoxetine; PBO = placebo; SD = standard deviation
  2. a p values were for comparing atomoxetine and placebo using a Fisher's exact test.
  3. b p values were for comparing atomoxetine and placebo using an ANOVA.